SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Peter Riedell, Kenneth R Carson, A drug safety evaluation of rituximab and risk of hepatitis B, Expert Opinion on Drug Safety, 2014, 13, 7, 977

    CrossRef

  2. 2
    Ludwig Kappos, Hans-Peter Hartung, Mark S Freedman, Alexey Boyko, Ernst Wilhelm Radü, Daniel D Mikol, Marc Lamarine, Yann Hyvert, Ulrich Freudensprung, Thomas Plitz, Johan van Beek, Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial, The Lancet Neurology, 2014, 13, 4, 353

    CrossRef

  3. 3
    C. de Andrés, R. Teijeiro, A. Saiz, P. Fernández, S. Sánchez-Ramón, Cambios en las Subpoblaciones de Linfocitos B y T en el Título de Anticuerpos Anti-Acuaporina-4 tras el Tratamiento de un Brote Agudo con Inmunoglobulinas y Rituximab, Neurología, 2014,

    CrossRef

  4. 4
    Jennifer Graves, Uma Vinayagasundaram, Ellen M. Mowry, Ian R. Matthews, Julia A. Marino, Jing Cheng, Emmanuelle Waubant, Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica, Multiple Sclerosis and Related Disorders, 2014, 3, 2, 244

    CrossRef

  5. 5
    Jaishree Bankoti, Leonard Apeltsin, Stephen L. Hauser, Simon Allen, Matthew E. Albertolle, H. Ewa Witkowska, H.-Christian von Büdingen, In multiple sclerosis, oligoclonal bands connect to peripheral B-cell responses, Annals of Neurology, 2014, 75, 2
  6. 6
    A. Salmen, R. Gold, A. Chan, Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system, Clinical & Experimental Immunology, 2014, 176, 2
  7. 7
    Stephen Krieger, Shawn F. Sorrells, Molly Nickerson, Thaddeus W.W. Pace, Mechanistic insights into corticosteroids in multiple sclerosis: War horse or chameleon?☆, Clinical Neurology and Neurosurgery, 2014, 119, 6

    CrossRef

  8. 8
    P. S. Rommer, A. Dudesek, O. Stüve, U.K. Zettl, Monoclonal antibodies in treatment of multiple sclerosis, Clinical & Experimental Immunology, 2014, 175, 3
  9. 9
    Nancy L Monson, Sterling B Ortega, Sara J Ireland, Anouk JM Meeuwissen, Ding Chen, Erik J Plautz, Erin Shubel, Xiangmei Kong, Min K Li, Laura H Freriks, Ann M Stowe, Repetitive hypoxic preconditioning induces an immunosuppressed B cell phenotype during endogenous protection from stroke, Journal of Neuroinflammation, 2014, 11, 1, 22

    CrossRef

  10. 10
    Shannon J. Beres, Jennifer Graves, Emmanuelle Waubant, Rituximab Use in Pediatric Central Demyelinating Disease, Pediatric Neurology, 2014, 51, 1, 114

    CrossRef

  11. 11
    Yusei Miyazaki, Masaaki Niino, Toshiyuki Fukazawa, Eri Takahashi, Takayuki Nonaka, Itaru Amino, Jun Tashiro, Naoya Minami, Naoto Fujiki, Shizuki Doi, Seiji Kikuchi, Suppressed pro-inflammatory properties of circulating B cells in patients with multiple sclerosis treated with fingolimod, based on altered proportions of B-cell subpopulations, Clinical Immunology, 2014, 151, 2, 127

    CrossRef

  12. 12
    Daniela Kao, Anja Lux, Inessa Schwab, Falk Nimmerjahn, Targeting B cells and autoantibodies in the therapy of autoimmune diseases, Seminars in Immunopathology, 2014, 36, 3, 289

    CrossRef

  13. You have free access to this content13
    Katie Streicher, Christopher A. Morehouse, Christopher J. Groves, Bhargavi Rajan, Fernanda Pilataxi, Kim P. Lehmann, Philip Z. Brohawn, Brandon W. Higgs, Kathleen McKeever, Steven A. Greenberg, David Fiorentino, Laura K. Richman, Bahija Jallal, Ronald Herbst, Yihong Yao, Koustubh Ranade, The Plasma Cell Signature in Autoimmune Disease, Arthritis & Rheumatology, 2014, 66, 1
  14. 14
    Joy Derwenskus, Fred D. Lublin, Multiple Sclerosis and Related Disorders, 2014,

    CrossRef

  15. 15
    Rhoanne C. McPherson, Stephen M. Anderton, Adaptive Immune Responses in CNS Autoimmune Disease: Mechanisms and Therapeutic Opportunities, Journal of Neuroimmune Pharmacology, 2013, 8, 4, 774

    CrossRef

  16. 16
    Judith Fraussen, Kathleen Vrolix, Nele Claes, Pilar Martinez-Martinez, Mario Losen, Raymond Hupperts, Bart Van Wijmeersch, Mercedes Espiño, Luisa M. Villar, Marc H. De Baets, Piet Stinissen, Veerle Somers, Autoantigen induced clonal expansion in immortalized B cells from the peripheral blood of multiple sclerosis patients, Journal of Neuroimmunology, 2013, 261, 1-2, 98

    CrossRef

  17. 17
    B. Diamond, G. Honig, S. Mader, L. Brimberg, B.T. Volpe, Brain-Reactive Antibodies and Disease, Annual Review of Immunology, 2013, 31, 1, 345

    CrossRef

  18. 18
    Claudio Gasperini, Shalom Haggiag, Serena Ruggieri, Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies, Expert Opinion on Investigational Drugs, 2013, 22, 10, 1243

    CrossRef

  19. 19
    Rehiana Ali, Richard St John Nicholas, Paolo Antonio Muraro, Drugs in Development for Relapsing Multiple Sclerosis, Drugs, 2013, 73, 7, 625

    CrossRef

  20. 20
    Sabeen Lulu, Emmanuelle Waubant, Humoral-Targeted Immunotherapies in Multiple Sclerosis, Neurotherapeutics, 2013, 10, 1, 34

    CrossRef

  21. 21
    Elena Giacomini, Martina Severa, Fabiana Rizzo, Rosella Mechelli, Viviana Annibali, Giovanni Ristori, Valeria Riccieri, Marco Salvetti, Eliana Marina Coccia, IFN-β therapy modulates B-cell and monocyte crosstalk via TLR7 in multiple sclerosis patients, European Journal of Immunology, 2013, 43, 7
  22. 22
    Dimitrios Karussis, Immunotherapy of Multiple Sclerosis, BioDrugs, 2013, 27, 2, 113

    CrossRef

  23. 23
    Paulus S. Rommer, Olaf Stüve, Management of Secondary Progressive Multiple Sclerosis: Prophylactic Treatment—Past, Present, and Future Aspects, Current Treatment Options in Neurology, 2013, 15, 3, 241

    CrossRef

  24. 24
    N. Molnarfi, U. Schulze-Topphoff, M. S. Weber, J. C. Patarroyo, T. Prod'homme, M. Varrin-Doyer, A. Shetty, C. Linington, A. J. Slavin, J. Hidalgo, D. E. Jenne, H. Wekerle, R. A. Sobel, C. C. A. Bernard, M. J. Shlomchik, S. S. Zamvil, MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies, Journal of Experimental Medicine, 2013, 210, 13, 2921

    CrossRef

  25. 25
    Erin E. Longbrake, Becky J. Parks, Anne H. Cross, Monoclonal Antibodies as Disease Modifying Therapy in Multiple Sclerosis, Current Neurology and Neuroscience Reports, 2013, 13, 11

    CrossRef

  26. 26
    Luisa Klotz, Heinz Wiendl, Monoclonal antibodies in neuroinflammatory diseases, Expert Opinion on Biological Therapy, 2013, 13, 6, 831

    CrossRef

  27. 27
    Sarah Lawrie, Amit Bar-Or, B cells set trends: Lessons from multiple sclerosis, Clinical and Experimental Neuroimmunology, 2012, 3, 3
  28. 28
    Sara J. Ireland, Monica Blazek, Christopher T. Harp, Benjamin Greenberg, Elliot M. Frohman, Laurie S. Davis, Nancy L. Monson, Antibody-independent B cell effector functions in relapsing remitting Multiple Sclerosis: Clues to increased inflammatory and reduced regulatory B cell capacity, Autoimmunity, 2012, 45, 5, 400

    CrossRef

  29. 29
    T. A. Barr, P. Shen, S. Brown, V. Lampropoulou, T. Roch, S. Lawrie, B. Fan, R. A. O'Connor, S. M. Anderton, A. Bar-Or, S. Fillatreau, D. Gray, B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells, Journal of Experimental Medicine, 2012, 209, 5, 1001

    CrossRef

  30. 30
    Juan Javier Servat, Katrina A Mears, Evan H Black, John J Huang, Biological agents for the treatment of uveitis, Expert Opinion on Biological Therapy, 2012, 12, 3, 311

    CrossRef

  31. 31
    Ilana B Katz Sand, Stephen Krieger, Emerging strategies for the treatment of multiple sclerosis, Future Neurology, 2012, 7, 2, 193

    CrossRef

  32. 32
    Elias Toubi, Shahar Nussbaum, Elsebeth Staun-Ram, Ayelet Snir, Doron Melamed, Liat Hayardeny, Ariel Miller, Laquinimod modulates B cells and their regulatory effects on T cells in Multiple Sclerosis, Journal of Neuroimmunology, 2012, 251, 1-2, 45

    CrossRef

  33. 33
    E. Ann Yeh, Management of Children with Multiple Sclerosis, Pediatric Drugs, 2012, 14, 3, 165

    CrossRef

  34. 34
    Henrik Gensicke, David Leppert, Özgür Yaldizli, Raija L.P. Lindberg, Matthias Mehling, Ludwig Kappos, Jens Kuhle, Monoclonal Antibodies and Recombinant Immunoglobulins for the Treatment of Multiple Sclerosis, CNS Drugs, 2012, 26, 1, 11

    CrossRef

  35. 35
    Shiv Saidha, Christopher Eckstein, Peter A. Calabresi, New and emerging disease modifying therapies for multiple sclerosis, Annals of the New York Academy of Sciences, 2012, 1247, 1
  36. 36
    Monica K. Mann, Avijit Ray, Sreemanti Basu, Christopher L. Karp, Bonnie N. Dittel, Pathogenic and regulatory roles for B cells in experimental autoimmune encephalomyelitis, Autoimmunity, 2012, 45, 5, 388

    CrossRef

  37. 37
    Mohammed A. Omair, Khalid A. Alnaqbi, Peter Lee, Rituximab in a patient with ankylosing spondylitis with demyelinating disease: a case report and review of the literature, Clinical Rheumatology, 2012, 31, 8, 1259

    CrossRef

  38. 38
    Robert P. Lisak, Joyce A. Benjamins, Liljana Nedelkoska, Jennifer L. Barger, Samia Ragheb, Boli Fan, Nadia Ouamara, Trina A. Johnson, Sathyanath Rajasekharan, Amit Bar-Or, Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro, Journal of Neuroimmunology, 2012, 246, 1-2, 85

    CrossRef

  39. 39
    Cecilia Ahlgren, Anders Odén, Tomas Bergström, Jan Lycke, Serum and CSF measles antibody levels increase over time in patients with multiple sclerosis or clinically isolated syndrome, Journal of Neuroimmunology, 2012, 247, 1-2, 70

    CrossRef

  40. 40
    De-Hyung Lee, Ralf A Linker, The role of myelin oligodendrocyte glycoprotein in autoimmune demyelination: a target for multiple sclerosis therapy?, Expert Opinion on Therapeutic Targets, 2012, 16, 5, 451

    CrossRef

  41. 41
    U.-C. Meier, G. Giovannoni, J. S. Tzartos, G. Khan, Translational Mini-Review Series on B cell subsets in disease. B cells in multiple sclerosis: drivers of disease pathogenesis and Trojan horse for Epstein–Barr virus entry to the central nervous system?, Clinical & Experimental Immunology, 2012, 167, 1
  42. 42
    Barbara Barun, Amit Bar-Or, Treatment of multiple sclerosis with Anti-CD20 antibodies, Clinical Immunology, 2012, 142, 1, 31

    CrossRef

  43. 43
    Guorong Liu, Kamaldeen A. Muili, Vrushali V. Agashe, Jeri-Anne Lyons, Unique B cell responses in B cell-dependent and B cell-independent EAE, Autoimmunity, 2012, 45, 3, 199

    CrossRef

  44. 44
    Katherine Buzzard, Simon Broadley, Helmut Butzkueven, What Do Effective Treatments for Multiple Sclerosis Tell Us about the Molecular Mechanisms Involved in Pathogenesis?, International Journal of Molecular Sciences, 2012, 13, 12, 12665

    CrossRef

  45. 45
    H-Christian von Büdingen, Amit Bar-Or, Scott S Zamvil, B cells in multiple sclerosis: connecting the dots, Current Opinion in Immunology, 2011, 23, 6, 713

    CrossRef

  46. 46
    Yolanda S. Kap, Jan Bauer, Nikki van Driel, Wim K. Bleeker, Paul W.H.I. Parren, Evert-Jan Kooi, Jeroen J.G. Geurts, Jon D. Laman, Jenny L. Craigen, Erwin Blezer, Bert A. 't Hart, B-Cell Depletion Attenuates White and Gray Matter Pathology in Marmoset Experimental Autoimmune Encephalomyelitis, Journal of Neuropathology and Experimental Neurology, 2011, 70, 11, 992

    CrossRef

  47. 47
    Andrew R Pachner, Experimental models of multiple sclerosis, Current Opinion in Neurology, 2011, 24, 3, 291

    CrossRef

  48. 48
    E. Ann Yeh, B. Weinstock-Guttman, Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis, Advances in Therapy, 2011, 28, 4, 270

    CrossRef

  49. 49
    Javier Carbone, Nadia del Pozo, Antonio Gallego, Elizabeth Sarmiento, Immunological risk factors for infection after immunosuppressive and biologic therapies, Expert Review of Anti-infective Therapy, 2011, 9, 4, 405

    CrossRef

  50. 50
    Brandon A. Brown, Mina Torabi, Incidence of Infusion-Associated Reactions with Rituximab for Treating Multiple Sclerosis, Drug Safety, 2011, 34, 2, 117

    CrossRef

  51. 51
    Anne H. Cross, Emmanuelle Waubant, MS and the B cell controversy, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2011, 1812, 2, 231

    CrossRef

  52. 52
    Stephen Krieger, Multiple Sclerosis Therapeutic Pipeline: Opportunities and Challenges, Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine, 2011, 78, 2
  53. 53
    Oscar Fernández, Nuevos fármacos para el tratamiento de la esclerosis múltiple, FMC - Formación Médica Continuada en Atención Primaria, 2011, 18, 9, 582

    CrossRef

  54. 54
    Hans Lassmann, Pathophysiology of inflammation and tissue injury in multiple sclerosis: What are the targets for therapy, Journal of the Neurological Sciences, 2011, 306, 1-2, 167

    CrossRef

  55. 55
    Gavin Giovannoni, Promising Emerging Therapies for Multiple Sclerosis, Neurologic Clinics, 2011, 29, 2, 435

    CrossRef

  56. 56
    Stephanie Knippenberg, Evelyn Peelen, Joost Smolders, Mariëlle Thewissen, Paul Menheere, Jan Willem Cohen Tervaert, Raymond Hupperts, Jan Damoiseaux, Reduction in IL-10 producing B cells (Breg) in multiple sclerosis is accompanied by a reduced naïve/memory Breg ratio during a relapse but not in remission, Journal of Neuroimmunology, 2011, 239, 1-2, 80

    CrossRef

  57. 57
    Lavnish Joshi, Sue L. Lightman, Alan D. Salama, Amy Lee Shirodkar, Charles D. Pusey, Simon R.J. Taylor, Rituximab in Refractory Ophthalmic Wegener's Granulomatosis, Ophthalmology, 2011, 118, 12, 2498

    CrossRef

  58. 58
    I. Gutierrez-Roelens, C. Galant, I. Theate, R. J. Lories, P. Durez, A. Nzeusseu-Toukap, B. Van den Eynde, F. A. Houssiau, B. R. Lauwerys, Rituximab treatment induces the expression of genes involved in healing processes in the rheumatoid arthritis synovium, Arthritis & Rheumatism, 2011, 63, 5
  59. 59
    Hans Lassmann, Jack van Horssen, The molecular basis of neurodegeneration in multiple sclerosis, FEBS Letters, 2011, 585, 23, 3715

    CrossRef

  60. 60
    Brenda Banwell, Amit Bar-Or, Gavin Giovannoni, Russell C. Dale, Marc Tardieu, Therapies for multiple sclerosis: considerations in the pediatric patient, Nature Reviews Neurology, 2011, 7, 2, 109

    CrossRef

  61. 61
    Dorothea Buck, Bernhard Hemmer, Treatment of multiple sclerosis: current concepts and future perspectives, Journal of Neurology, 2011, 258, 10, 1747

    CrossRef

  62. 62
    Jennifer Graves, Emmanuelle L Waubant, Addressing Unmet Medical Needs in Relapsing–Remitting Multiple Sclerosis, 2011,

    CrossRef

  63. 63
    Amit Bar-Or, Lama Fawaz, Boli Fan, Peter J. Darlington, Aja Rieger, Christine Ghorayeb, Peter A. Calabresi, Emmanuelle Waubant, Stephen L. Hauser, Jiameng Zhang, Craig H. Smith, Abnormal B-cell cytokine responses a trigger of T-cell–mediated disease in MS?, Annals of Neurology, 2010, 67, 4
  64. 64
    Vitaly Ablamunits, Brygida Bisikirska, Kevan C. Herold, Acquisition of regulatory function by human CD8+ T cells treated with anti-CD3 antibody requires TNF, European Journal of Immunology, 2010, 40, 10
  65. 65
    K.C. O'Connor, C. Lopez-Amaya, D. Gagne, L. Lovato, N.H. Moore-Odom, J. Kennedy, L. Krupp, S. Tenembaum, J. Ness, A. Belman, A. Boyko, O. Bykova, J.K. Mah, C.A. Stoian, E. Waubant, M. Kremenchutzky, M. Ruggieri, M.R. Bardini, M. Rensel, J. Hahn, B. Weinstock-Guttman, E.A. Yeh, K. Farrell, M.S. Freedman, M. Iivanainen, V. Bhan, M. Dilenge, M.A. Hancock, D. Gano, R. Fattahie, L. Kopel, A.E. Fournier, M. Moscarello, B. Banwell, A. Bar-Or, Anti-myelin antibodies modulate clinical expression of childhood multiple sclerosis, Journal of Neuroimmunology, 2010, 223, 1-2, 92

    CrossRef

  66. 66
    Manuel Comabella, Xavier Montalban, Kristina Kakalacheva, Deeqa Osman, Falk Nimmerjahn, Mar Tintoré, Jan D. Lünemann, B cell expression of the inhibitory Fcγ receptor is unchanged in early MS, Journal of Neuroimmunology, 2010, 223, 1-2, 135

    CrossRef

  67. 67
    Michael J. Townsend, John G. Monroe, Andrew C. Chan, B-cell targeted therapies in human autoimmune diseases: an updated perspective, Immunological Reviews, 2010, 237, 1
  68. 68
    Rachel A. Farrell, Gavin Giovannoni, Current and Future Role of Interferon Beta in the Therapy of Multiple Sclerosis, Journal of Interferon & Cytokine Research, 2010, 30, 10, 715

    CrossRef

  69. 69
    Andreas P Lysandropoulos, Renaud A Du Pasquier, Demyelination as a complication of new immunomodulatory treatments, Current Opinion in Neurology, 2010, 23, 3, 226

    CrossRef

  70. 70
    Jan D. Lünemann, Mar Tintoré, Brady Messmer, Till Strowig, Álex Rovira, Héctor Perkal, Estrella Caballero, Christian Münz, Xavier Montalban, Manuel Comabella, Elevated Epstein–Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis, Annals of Neurology, 2010, 67, 2
  71. 71
    Laureline Berthelot, Patrick Miqueu, Ségolène Pettré, Marina Guillet, Julien Moynard, Sandrine Wiertlewski, Fabienne Lefrère, Sophie Brouard, Jean-Paul Soulillou, David-Axel Laplaud, Failure of glatiramer acetate to modify the peripheral T cell repertoire of relapsing–remitting multiple sclerosis patients, Clinical Immunology, 2010, 135, 1, 33

    CrossRef

  72. 72
    Leslie J. Marshall, Eugene O. Major, Molecular Regulation of JC Virus Tropism: Insights into Potential Therapeutic Targets for Progressive Multifocal Leukoencephalopathy, Journal of Neuroimmune Pharmacology, 2010, 5, 3, 404

    CrossRef

  73. 73
    Arturo Mangas, Rafael Coveñas, Michel Geffard, New drug therapies for multiple sclerosis, Current Opinion in Neurology, 2010, 23, 3, 287

    CrossRef

  74. 74
    Joanne L. Jones, Alasdair J. Coles, New treatment strategies in multiple sclerosis, Experimental Neurology, 2010, 225, 1, 34

    CrossRef

  75. You have free access to this content75
    Alexandra Schröder, Ralf A. Linker, Ralf Gold, Plasmapheresis for neuroinflammatory disorders, Clinical and Experimental Neuroimmunology, 2010, 1, 3
  76. 76
    Mathias Buttmann, Treating multiple sclerosis with monoclonal antibodies: a 2010 update, Expert Review of Neurotherapeutics, 2010, 10, 5, 791

    CrossRef

  77. 77
    Heinz Wiendl, Nico Melzer, Christoph Kleinschnitz, Sven G. Meuth, MULTIPLE SCLEROSIS 3, 2010,

    CrossRef

  78. 78
    Rachel B. Jones, Alastair J. Ferraro, Afzal N. Chaudhry, Paul Brogan, Alan D. Salama, Kenneth G. C. Smith, Caroline O. S. Savage, David R. W. Jayne, A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody–associated vasculitis, Arthritis & Rheumatism, 2009, 60, 7
  79. 79
    Hakan M. Gürcan, Derin B. Keskin, Joel N.H. Stern, Matthew A. Nitzberg, Haris Shekhani, A. Razzaque Ahmed, A review of the current use of rituximab in autoimmune diseases, International Immunopharmacology, 2009, 9, 1, 10

    CrossRef

  80. 80
    Gregory P. Owens, Jeffrey L. Bennett, Hans Lassmann, Kevin C. O'Connor, Alanna M. Ritchie, Andrew Shearer, Chiwah Lam, Xiaoli Yu, Marius Birlea, Cecily DuPree, R. Anthony Williamson, David A. Hafler, Mark P. Burgoon, Don Gilden, Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid, Annals of Neurology, 2009, 65, 6
  81. 81
    Takashi Matsushita, Thomas F Tedder, B-lymphocyte depletion for the treatment of multiple sclerosis: now things really get interesting, Expert Review of Neurotherapeutics, 2009, 9, 3, 309

    CrossRef

  82. 82
    T. Menge, H.-C. Büdingen, M.C. Dalakas, B.C. Kieseier, H.-P. Hartung, B-Zell-gerichtete Multiple-Sklerose-Therapie, Der Nervenarzt, 2009, 80, 2, 190

    CrossRef

  83. 83
    Thomas Dörner, David Isenberg, David Jayne, Heinz Wiendl, Detlef Zillikens, Gerd Burmester, Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis, Autoimmunity Reviews, 2009, 9, 2, 82

    CrossRef

  84. 84
    Melody Ryan, Drug Therapies for the Treatment of Multiple Sclerosis, Journal of Infusion Nursing, 2009, 32, 3, 137

    CrossRef

  85. 85
    Jan D. Lünemann, Christian Münz, EBV in MS: guilty by association?, Trends in Immunology, 2009, 30, 6, 243

    CrossRef

  86. 86
    A. Schröder, G. Ellrichmann, G. Chehab, M. Schneider, R.A. Linker, R. Gold, Einsatz von Rituximab in der Behandlung neuroimmunologischer Erkrankungen, Der Nervenarzt, 2009, 80, 2, 155

    CrossRef

  87. 87
    Paul S Giacomini, Peter J Darlington, Amit Bar-Or, Emerging multiple sclerosis disease-modifying therapies, Current Opinion in Neurology, 2009, 22, 3, 226

    CrossRef

  88. 88
    Iñaki Sanz, Indications of Rituximab in autoimmune diseases, Drug Discovery Today: Therapeutic Strategies, 2009, 6, 1, 13

    CrossRef

  89. 89
    Aimee Pasqua Borazanci, Meghan K Harris, Robert N Schwendimann, Eduardo Gonzalez-Toledo, Amir H Maghzi, Masoud Etemadifar, Nadejda Alekseeva, James Pinkston, Roger E Kelley, Alireza Minagar, Multiple sclerosis: clinical features, pathophysiology, neuroimaging and future therapies, Future Neurology, 2009, 4, 2, 229

    CrossRef

  90. 90
    E William St Clair, Novel targeted therapies for autoimmunity, Current Opinion in Immunology, 2009, 21, 6, 648

    CrossRef

  91. 91
    Joseph R. Berger, Sidney Houff, Opportunistic infections and other risks with newer multiple sclerosis therapies, Annals of Neurology, 2009, 65, 4
  92. 92
    Alexandra Schröder, Ralf A Linker, Ralf Gold, Plasmapheresis for neurological disorders, Expert Review of Neurotherapeutics, 2009, 9, 9, 1331

    CrossRef

  93. 93
    Vickie McDonald, Maria Leandro, Rituximab in non-haematological disorders of adults and its mode of action, British Journal of Haematology, 2009, 146, 3
  94. 94
    Kathleen Hawker, Paul O'Connor, Mark S. Freedman, Peter A. Calabresi, Jack Antel, Jack Simon, Stephen Hauser, Emmanuelle Waubant, Timothy Vollmer, Hillel Panitch, Jiameng Zhang, Peter Chin, Craig H. Smith, Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial, Annals of Neurology, 2009, 66, 4
  95. 95
    M. C. Levesque, Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders, Clinical & Experimental Immunology, 2009, 157, 2
  96. 96
    Hisaji Imamura, Masami Tanaka, Naoyuki Kitagawa, Masayuki Tahara, Miki Oono, Keiko Tanaka, Tetsuro Konishi, Trial of rituximab in three patients with neuromyelitis optica, Rinsho Shinkeigaku, 2009, 49, 8, 457

    CrossRef

  97. 97
    Brian C. Healy, Douglas L. Hayden, Mehul P. Sampat, Rohit Bakshi, Charles R.G. Guttmann, Unbiased treatment effect estimates by modeling the disease process of multiple sclerosis, Journal of the Neurological Sciences, 2009, 278, 1-2, 54

    CrossRef

  98. 98
    Marinos C Dalakas, B cells as therapeutic targets in autoimmune neurological disorders, Nature Clinical Practice Neurology, 2008, 4, 10, 557

    CrossRef

  99. 99
    H. Wiendl, K. V. Toyka, P. Rieckmann, R. Gold, H.-P. Hartung, R. Hohlfeld, Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations, Journal of Neurology, 2008, 255, 10, 1449

    CrossRef

  100. 100
    Til Menge, Martin S Weber, Bernhard Hemmer, Bernd C Kieseier, Hans-Christian von Büdingen, Clemens Warnke, Scott S Zamvil, Aaron Boster, Omar Khan, Hans-Peter Hartung, Olaf Stüve, Disease-Modifying Agents for Multiple Sclerosis, Drugs, 2008, 68, 17, 2445

    CrossRef

  101. 101
    Andreas Lutterotti, Roland Martin, Getting specific: monoclonal antibodies in multiple sclerosis, The Lancet Neurology, 2008, 7, 6, 538

    CrossRef

  102. 102
    Ralf A. Linker, Bernd C. Kieseier, Ralf Gold, Identification and development of new therapeutics for multiple sclerosis, Trends in Pharmacological Sciences, 2008, 29, 11, 558

    CrossRef

  103. 103
    P. S. Rommer, O. Stüve, R. Goertsches, E. Mix, U. K. Zettl, Monoclonal antibodies in the therapy of multiple sclerosis, Journal of Neurology, 2008, 255, S6, 28

    CrossRef

  104. 104
    Sven G. Meuth, Christoph Kleinschnitz, Heinz Wiendl, Recent clinical trials and future therapies, Journal of Neurology, 2008, 255, S6, 93

    CrossRef

  105. 105
    Rituximab in Relapsing–Remitting Multiple Sclerosis, New England Journal of Medicine, 2008, 358, 24, 2645

    CrossRef

  106. 106
    R.A. Linker, B.C. Kieseier, Therapieentscheidungen bei Multipler Sklerose, Der Nervenarzt, 2008, 79, 10, 1123

    CrossRef

  107. 107
    Dirk Reske, Walter F Haupt, Use of rituximab in multiple sclerosis: current progress and future perspectives, Expert Review of Clinical Immunology, 2008, 4, 5, 573

    CrossRef

  108. 108
    Dian He, Hongyu Zhou, Wenjie Han, Shihong Zhang, Rituximab for relapsing-remitting multiple sclerosis, The Cochrane Library,
  109. 109
    M. Filippi, M. A. Rocca, D. L. Arnold, R. Bakshi, F. Barkhof, N. De Stefano, F. Fazekas, E. Frohman, D. H. Miller, J. S. Wolinsky, Use of Imaging in Multiple Sclerosis,